An analogous situation is the greater glycemic response of racial groups that have a relatively high carbohydrate intake, including East Asians, to sitagliptin in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in type 2 diabetes [23], albeit to endogenous incretins rather than GLP-1 RA pharmacotherapy. Here, GLP1R is linked to type 2 diabetes mellitus.